Mosaic Laboratories has been acquired by Caprion HistoGeneX
The shareholders of Mosaic Laboratories have sold the company to Caprion HistoGeneX.
Founded in 2005 by Lisa Dauffenbach and Chris Kerfoot, Mosaic Laboratories is a Lake Forest, California-based leading provider of bio-analytical testing services supporting translational, preclinical and clinical trial studies for a marquee roster of biotech and pharmaceutical clients globally. Mosaic pioneered proprietary multiplex immunohistochemistry (IHC) services that provide a superior ability to evaluate multiple biomarkers in a single tissue section, and has built a reputation among pharmaceutical companies to produce the most vivid IHC biomarker images. Mosaic supports the most rigorous clinical trial programs in the world, thereby impacting the future of patient therapies for cancer and other diseases.
Caprion HistoGeneX is a provider of proteomics and immune monitoring services for the pharmaceutical and biotechnology industry. The company operates two proprietary immune monitoring platforms that offer multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses while its proteomics business unit, as well as gel-free, label-free mass spectrometry (MS), provide comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers.
Oaklins’ team in Los Angeles acted as advisor to the seller in this transaction.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Related deals
Bolster Investment Partners has acquired a majority stake in Eternal Sun
Bolster Investment Partners, a Netherlands-based investment firm, has acquired a majority stake in Eternal Sun, a global technology leader in advanced solar panel testing equipment, from ABN AMRO Sustainable Impact Fund, a private impact fund based in the Netherlands, and Vermec, a Belgium-based investment firm.
Learn moreCerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn moreiwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Learn more